Abbott Laboratories faces a criminal investigation by the Justice Department, after its recall of formulas due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The Justice Department was investigating conduct at Abbott’s plant in Sturgis, Michigan,
According to an Abbott spokesman, they are fully cooperating with the Justice Department without specifying what aspect of the company is under scrutiny.
In February 2022, Abbott, the biggest US supplier of baby formula, recalled Similac and other infant formula products produced at its Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The US Food and Drug Administration found "shocking" results during an inspection, such as cracks in vital equipment, inadequate hand-washing, and evidence of previous bacterial contamination.
The plant has since reopened.


GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Epstein Files Released by DOJ Spotlight Bill Clinton, Raise Questions Over Trump Mentions
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Russian Stocks End Lower as Energy and Mining Shares Weigh on MOEX Index
Gold and Silver Hit Record Highs as Safe-Haven Demand Surges Amid Global Uncertainty
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Preservation Group Sues Trump Administration to Halt $300 Million White House Ballroom Project
BOJ Governor Signals Gradual Rate Hikes as Japan’s Inflation Nears 2% Target
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 



